1
|
Lan Y, Tao W, Ma L, Wang X, Li H, Du Y, Yang R, Wu S, Ou Y, Liu X, Huang Y, Zhou Y. The RNA sequencing results revealed the expression of different genes and signaling pathways during chemotherapy resistance in peripheral T-cell lymphoma. BMC Med Genomics 2024; 17:74. [PMID: 38468267 DOI: 10.1186/s12920-024-01842-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2023] [Accepted: 02/29/2024] [Indexed: 03/13/2024] Open
Abstract
BACKGROUND Peripheral T-cell lymphoma (PTCL) is a subtype of non-Hodgkin's lymphoma that occurs primarily at extranodal sites and is commonly treated using chemotherapy and radiotherapy. PTCL is more malignant than other lymphoid tumors, resulting in a poor prognosis.The 5-year recurrence rate remains high, and there is a lack of standard treatment for patients with relapse-resistant disease. However, the molecular mechanisms underlying the resistance of peripheral T-cell lymphoma cells to chemotherapeutic drugs, as well as identifying strategies to overcome drug resistance remains unclear. In this study, we aimed to identify pivotal genes and signaling pathways associated with chemotherapy resistance in PTCL. METHODS In this study, a total of 5 healthy controls and 7 clinical patients were enrolled; 4 patients were classified as chemotherapy sensitive, and 3 patients were classified as chemotherapy resistant. Peripheral blood samples were collected from each participant, and total RNA was extracted from the white blood cells. RNA sequencing was conducted on the Illumina HiSeq platform to obtain comprehensive gene expression profiles. Subsequently, the expression patterns of the DEGs associated with the most enriched signaling pathways, with a special focus on cancer-related genes, were validated using quantitative real-time polymerase chain reaction (qRT-PCR) in peripheral TCL patients. RESULTS RNA sequencing (RNA-seq) analysis revealed 4063 differentially expressed genes (DEGs) in peripheral T-cell lymphoma specimens from patients with chemotherapy resistance, of which 1128 were upregulated and 2935 were downregulated. Subsequent quantitative gene expression analysis confirmed a differential expression pattern in all the libraries, with 9 downregulated genes and 10 upregulated genes validated through quantitative real-time PCR in 6 clinical specimens from patients with chemotherapy resistance. KEGG pathway analysis revealed significant alterations in several pathways, with 6 downregulated pathways and 9 upregulated pathways enriched in the DEGs. Notably, the TNF signaling pathway, which is extensively regulated, was among the pathways that exhibited significant changes. These findings suggest that DEGs and the TNF signaling pathway may play crucial roles in chemotherapy resistance in peripheral T-cell lymphoma. CONCLUSION Our study revealed that the expression of specific genes, including TNFRSF1B, TRADD2, and MAP3K7, may play an important role in chemotherapy resistance in peripheral T-cell lymphoma. Moreover, we identified the downregulation of the TNF signaling pathway, a crucial pathway involved in cell survival, death, and differentiation, as a potential contributor to the development of chemotherapy resistance in peripheral T-cell lymphoma. These findings provide valuable insights into the molecular mechanisms underlying chemotherapy resistance and highlight potential targets for overcoming treatment resistance in this challenging disease.
Collapse
Affiliation(s)
- Yunyi Lan
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China.
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China.
| | - Wei Tao
- Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Luyao Ma
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Xiaoxiong Wang
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Hongsheng Li
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Yaxi Du
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Ruijiao Yang
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Shunxian Wu
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Yingxin Ou
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Xin Liu
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Yunchao Huang
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| | - Yongchun Zhou
- Molecular Diagnostic Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, China
- International Joint Laboratory On High Altitude Regional Cancer, Kunming, China
- Yunnan Key Laboratory of Lung Cancer Research, Kunming, China
| |
Collapse
|
2
|
Huang B, Tian L, Chen Z, Zhang L, Su W, Lu T, Yang Y, Hui R, Wang X, Fan X. Angiopoietin 2 as a Novel Potential Biomarker for Acute Aortic Dissection. Front Cardiovasc Med 2022; 8:743519. [PMID: 35004874 PMCID: PMC8733161 DOI: 10.3389/fcvm.2021.743519] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 11/05/2021] [Indexed: 01/16/2023] Open
Abstract
Biomarker-assisted diagnosis of acute aortic dissection (AAD) is important for initiation of treatment and improved survival. However, identification of biomarkers for AAD in blood is a challenging task. The present study aims to find the potential AAD biomarkers using a transcriptomic strategy. Arrays based genome-wide gene expression profiling were performed using ascending aortic tissues which were collected from AAD patients and healthy donors. The differentially expressed genes were validated using quantitative reverse transcriptase PCR (qRT-PCR) and western blot. The plasma levels of a potential biomarker, angiopoietin 2 (ANGPT2) were determined in case-control cohort (77 AAD patients and 82 healthy controls) by enzyme linked immunosorbent assay. Receiver operating characteristic curve (ROC) was used to evaluate the diagnostic power of ANGPT2 for AAD. Transcriptome data demonstrated that a total of 18 genes were significantly up-regulated and 28 genes were significantly down-regulated among AAD tissues (foldchange>3.0, p < 0.01). By bioinformatic analysis, we identified ANGPT2 as a candidate biomarker for blood-based detection of AAD. The qRT-PCR and protein expression demonstrated that ANGPT2 increased 2.4- and 4.2 folds, respectively in aortic tissue of AAD patients. Immunohistochemical staining demonstrated that ANGPT2 was markedly increased in intima of the aortic wall in AAD. Furthermore, ANGPT2 was significantly elevated in AAD patients as compared with controls (median 1625 vs. 383 pg/ml, p < 1E-6). ROC curve analysis showed that ANGPT2 was highly predictive of a diagnosis of type A AAD (area under curve 0.93, p < 1E-6). Sensitivity and specificity were 81 and 90%, respectively at the cutoff value of 833 pg/ml. In conclusion, ANGPT2 could be a promising biomarker for diagnosis of AAD; however, more studies are still needed to verify its specificity in diagnosing of AAD.
Collapse
Affiliation(s)
- Bi Huang
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Li Tian
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Zhaoran Chen
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,Department of Geriatrics and Gerontology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Liang Zhang
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Wenjun Su
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Tianyi Lu
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Yanmin Yang
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Rutai Hui
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xiaojian Wang
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xiaohan Fan
- State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| |
Collapse
|